These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38347759)

  • 61. Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data.
    Chlebus K; Cybulska B; Dobrowolski P; Romanowska-Kocejko M; Żarczyńska-Buchowiecka M; Gilis-Malinowska N; Stróżyk A; Borowiec-Wolna J; Pajkowski M; Bobrowska B; Rajtar-Salwa R; Kwapiszewska A; Waluś-Miarka M; Chmara M; Gałąska R; Małecki M; Zdrojewski T; Gruchała M
    Cardiol J; 2022; 29(1):62-71. PubMed ID: 35146730
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
    Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
    J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.
    Durairaj A; Sabates A; Nieves J; Moraes B; Baum S
    Curr Treat Options Cardiovasc Med; 2017 Aug; 19(8):58. PubMed ID: 28639183
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Status of PCSK9 Monoclonal Antibodies in Australia.
    Scherer DJ; Nelson AJ; O'Brien R; Kostner KM; Hare DL; Colquhoun DM; Barter PJ; Aylward P; Nicholls SJ; Watts GF
    Heart Lung Circ; 2019 Oct; 28(10):1571-1579. PubMed ID: 31104887
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anti PCSK9 Monoclonal Antibody Treatment in Elderly Patients: A Real-world Clinical Experience.
    Giladi E; Israel R; Daud W; Gurevitz C; Atamna A; Pereg D; Assali A; Elis A
    Isr Med Assoc J; 2024 Feb; 26(2):130-135. PubMed ID: 38420988
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of clinical pharmacist interventions on cost in an integrated health system specialty pharmacy.
    Lankford C; Dura J; Tran A; Lam SW; Naelitz B; Willner M; Geyer K
    J Manag Care Spec Pharm; 2021 Mar; 27(3):379-384. PubMed ID: 33645240
    [No Abstract]   [Full Text] [Related]  

  • 67. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies.
    Seidah NG
    Curr Pharm Des; 2013; 19(17):3161-72. PubMed ID: 23317404
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia.
    White CM
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):301-308. PubMed ID: 29649884
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD; Aday AW; Rose LM; Ridker PM
    Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
    Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
    Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials.
    Casula M; Olmastroni E; Boccalari MT; Tragni E; Pirillo A; Catapano AL
    Pharmacol Res; 2019 May; 143():143-150. PubMed ID: 30926528
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.
    Baruch A; Luca D; Kahn RS; Cowan KJ; Leabman M; Budha NR; Chiu CPC; Wu Y; Kirchhofer D; Peterson A; Davis JC; Tingley WG
    Clin Cardiol; 2017 Jul; 40(7):503-511. PubMed ID: 28326559
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In-hospital initiation of a PCSK9 inhibitor in patients with acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Shi W; Xu Y; Zhou L; Wang W; Huang W; Zhou B
    Medicine (Baltimore); 2024 Mar; 103(10):e37416. PubMed ID: 38457555
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes.
    AlTurki A; Marafi M; Dawas A; Dube MP; Vieira L; Sherman MH; Gregoire J; Thanassoulis G; Tardif JC; Huynh T
    Am J Cardiol; 2019 Dec; 124(12):1869-1875. PubMed ID: 31679643
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center.
    Tsai CL; Chang YH; Su CH; Wu YJ; Yeh HI; Lin CF
    J Formos Med Assoc; 2022 Sep; 121(9):1877-1880. PubMed ID: 34852937
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
    Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
    Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.
    Schreml J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1538-1548. PubMed ID: 28618994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.